Anixa Biosciences, Inc. ANIX
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $8.00 (+203.0% upside)
Key Stats
- Today's Range
- $2.63 – $2.82
- 50-Day Range
- $2.56 – $3.87
- 52-Week Range
- $2.32 – $5.46
- Volume
- 184K shs
- Average Volume
- 341K shs
- Market Cap
- $92.82 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 4.11%
- Days to Cover
- 7.09
About Anixa Biosciences, Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Related Stocks
Compare head-to-head: ANIX vs LLY·ANIX vs JNJ·ANIX vs ABBV·ANIX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.